European strategies till 1997

Country Description
European Union
587.gif (924 byte)development of an Orphan Drug policy is part of the 1996 work program

587.gif (924 byte) the policy is likely to include:

  • designation based on prevalence of disease in the population of less than 0.05% (about 180 000 patients) AND no expectation of profitability AND subject to review and withdrawal if criteria no longer apply

  • shared cost program to support research in addition to the BIOMED program already in place

  • monitored release program in addition to the current provision which permits marketing authorization for some drugs based on a limited dossier

  • development of a telematic network to facilitate clinical trials and research

587.gif (924 byte) legislation is already in place providing market exclusivity and provisions for fee exemptions under cost recovery

587.gif (924 byte)many member states already have incentives in place for R&D related to orphan diseases

587.gif (924 byte)individual member states control access to drugs through their own programs (see France, U.K.)

587.gif (924 byte) no Orphan Drug policy but leading initiatives in the E.U. (see E.U.)

587.gif (924 byte) temporary approval (ATU) for "orphan" drugs may be granted based on available data for a time period of 3 months to 1 year

587.gif (924 byte) approval may apply to a cohort of patients or may require release on an individual patient basis


587.gif (924 byte) no Orphan Drug policy (see E.U.)

587.gif (924 byte) historically, some government research funds have been made available for the development of drugs for rare diseases

587.gif (924 byte) practitioners can procure unapproved drugs for individual patients based on clinical judgement

587.gif (924 byte) an Application Under Exceptional Circumstances can be made when insufficient information on the safety, quality and/or efficacy of a product exists or when it may be unethical to collect such information. Manufacturers must detail PMS studies to be undertaken.

587.gif (924 byte) provision for abating fees for NDA for small market drugs under cost recovery

freccesn.gif (3942 byte)Previous

freccedx.gif (3954 byte)